BACKGROUND: Mucolipidoses II and III alpha/beta (ML II and ML III) are lysosomal disorders in which the essential mannose 6-phosphate recognition marker is not synthesised on to lysosomal hydrolases and other glycoproteins. The disorders are caused by mutations in GNPTAB, which encodes two of three subunits of the heterohexameric enzyme, N-acetylglucosamine-1-phosphotransferase. OBJECTIVES: Clinical, biochemical and molecular findings in 61 probands (63 patients) are presented to provide a broad perspective of these mucolipidoses. METHODS: GNPTAB was sequenced in all probands and/or parents. The activity of several lysosomal enzymes was measured in plasma, and GlcNAc-1-phosphotransferase was assayed in leucocytes. Thirty-six patients were studied in detail, allowing extensive clinical data to be abstracted. RESULTS: ML II correlates with near-total absence of phosphotransferase activity resulting from homozygosity or compound heterozygosity for frameshift or nonsense mutations. Craniofacial and orthopaedic manifestations are evident at birth, skeletal findings become more obvious within the first year, and growth is severely impaired. Speech, ambulation and cognitive function are impaired. ML III retains a low level of phosphotransferase activity because of at least one missense or splice site mutation. The phenotype is milder, with minimal delays in milestones, the appearance of facial coarsening by early school age, and slowing of growth after the age of 4 years. CONCLUSIONS: Fifty-one pathogenic changes in GNPTAB are presented, including 42 novel mutations. Ample clinical information improves criteria for delineation of ML II and ML III. Phenotype-genotype correlations suggested in more general terms in earlier reports on smaller groups of patients are specified and extended.
BACKGROUND: Mucolipidoses II and III alpha/beta (ML II and ML III) are lysosomal disorders in which the essential mannose 6-phosphate recognition marker is not synthesised on to lysosomal hydrolases and other glycoproteins. The disorders are caused by mutations in GNPTAB, which encodes two of three subunits of the heterohexameric enzyme, N-acetylglucosamine-1-phosphotransferase. OBJECTIVES: Clinical, biochemical and molecular findings in 61 probands (63 patients) are presented to provide a broad perspective of these mucolipidoses. METHODS:GNPTAB was sequenced in all probands and/or parents. The activity of several lysosomal enzymes was measured in plasma, and GlcNAc-1-phosphotransferase was assayed in leucocytes. Thirty-six patients were studied in detail, allowing extensive clinical data to be abstracted. RESULTS:ML II correlates with near-total absence of phosphotransferase activity resulting from homozygosity or compound heterozygosity for frameshift or nonsense mutations. Craniofacial and orthopaedic manifestations are evident at birth, skeletal findings become more obvious within the first year, and growth is severely impaired. Speech, ambulation and cognitive function are impaired. ML III retains a low level of phosphotransferase activity because of at least one missense or splice site mutation. The phenotype is milder, with minimal delays in milestones, the appearance of facial coarsening by early school age, and slowing of growth after the age of 4 years. CONCLUSIONS: Fifty-one pathogenic changes in GNPTAB are presented, including 42 novel mutations. Ample clinical information improves criteria for delineation of ML II and ML III. Phenotype-genotype correlations suggested in more general terms in earlier reports on smaller groups of patients are specified and extended.
Authors: A Raas-Rothschild; R Bargal; O Goldman; E Ben-Asher; J E M Groener; A Toutain; E Stemmer; Z Ben-Neriah; H Flusser; F A Beemer; M Penttinen; T Olender; A J J T Rein; G Bach; M Zeigler Journal: J Med Genet Date: 2004-04 Impact factor: 6.318
Authors: Stephan Tiede; Stephan Storch; Torben Lübke; Bernard Henrissat; Ruth Bargal; Annick Raas-Rothschild; Thomas Braulke Journal: Nat Med Date: 2005-10-02 Impact factor: 53.440
Authors: Stephan Tiede; Nicole Muschol; Gert Reutter; Michael Cantz; Kurt Ullrich; Thomas Braulke Journal: Am J Med Genet A Date: 2005-09-01 Impact factor: 2.802
Authors: Richard A Steet; Roger Hullin; Mariko Kudo; Michele Martinelli; Nils U Bosshard; Thomas Schaffner; Stuart Kornfeld; Beat Steinmann Journal: Am J Med Genet A Date: 2005-02-01 Impact factor: 2.802
Authors: Alicia C Castonguay; Yi Lasanajak; Xuezheng Song; Linda J Olson; Richard D Cummings; David F Smith; Nancy M Dahms Journal: Glycobiology Date: 2012-02-27 Impact factor: 4.313
Authors: Jules G Leroy; David Sillence; Tim Wood; Jarrod Barnes; Robert Roger Lebel; Michael J Friez; Roger E Stevenson; Richard Steet; Sara S Cathey Journal: Eur J Hum Genet Date: 2013-09-18 Impact factor: 4.246